PTO-144	9 REPRO	DDUCED	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716
011	FERMA	ECOND SUPPLEMENTAL TION DISCLOSURE CITATION AN AN APPLICATION	APPLICANT David A. Edwards, et a	11.
APR 1	1 <b>2003</b> Use se	april 2, 2003 gral sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO. GROUP 1615
TRAI		<del></del>	J.S. PATENT DOCUMENTS	-
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	ва	2,470,296	05/17/49	Fields
	BB	2,533,065	12/05/50	Taplin et al.
	вс	2,992,645	07/18/61	Fowler
	BD	3,781,230	12/25/73	Vassiliades et al.
	BE	3,957,965	05/18/76	Harley et al.
	BF	4,009,280	02/22/77	Macarthur et al.
	BG	4,089,800	05/16/78	Temple
	вн	4,161,516	07/17/79	Bell
	BI	4,173,488	11/06/79	Vassiliades <i>et al</i> .
	BJ	4,272,398	06/09/81	Jaffe
	вк	4,352,883	10/05/82	Lim
	BA2	4,391,909	07/05/83	Lim
	BB2	4,466,442	08/21/84	Hilmann et al.
	BC2	4,480,041	10/30/84	Myles <i>et al</i> .
	BD2	4,524,769	06/25/85	Wetterlin
	BE2	4,572,203	02/25/86	Feinstein
	BF2	4,590,206	05/20/86	Forrester et al.
	BG2	4,615,697	10/07/86	Robinson
	вн2	4,679,555	07/14/87	Sackner
	BI2	4,741,872	05/03/88	De Luca et al.
	вј2	4,743,545	05/10/88	Torobin
	вк2	4,774,958	10/04/88	Feinstein
	ваз	4,789,550	12/06/88	Hommel et al.
	ввз	4,818,542	04/04/89	De Luca et al.
	BC3	4,847,091	07/11/89	Illum
	BD3	4,855,144	08/08/89	Leong et al.
	BE3	4,857,311	08/15/89	Domb et al.
EXAMIN	NER		DATE CONSIDERED	

Pro-1449 REPRODUCED			ATTORNEY DOCKET NO. 2685.1003-008 APPLICATION NO. 09/822,716	
ONFORMATION DISCLOSURE CITATION THE AN APPLICATION  APR 1 1 2003 April 2, 2003  (Use several sheets if necessary)		IN APPLICATION	APPLICANT David A. Edwards, et al.	
			FILING DATE March 30, 2001	CONFIRMATION NO. GROUP 1615
			U.S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	BF3	4,861,627	08/29/89	Mathiowitz et al.
	BG3	4,865,789	09/12/89	Castro et al.
	внз	This reference number intentionally left blank		
	BI3	4,904,479	02/27/90	Illum
	вјз	4,917,119	04/17/90	Potter et al.
	вкз	4,963,297	10/16/90	Madden
	BA4	4,976,968	12/11/90	Steiner
	BB4	4,994,281	02/19/91	Muranishi et al.
	BC4	This reference number intentionally left blank		
	BD4	5,033,463	07/23/91	Cocozza
	BE4	5,064,650	11/12/91	Lew
	BF4	5,069,936	12/03/91	Yen
	BG4	5,075,109	12/24/91	Tice et al.
	вн4	5,100,669	03/31/92	Hyon et al.
	BI4	5,123,414	06/23/92	Unger
	BJ4	5,145,684	09/08/92	Liversidge et al.
	BK4	5,160,745	11/03/92	De Luca et al.
	BA5	5,169,871	12/08/92	Hughes et al.
	BB5	5,174,988	12/29/92	Mautone et al.
	BC5	5,195,520	03/23/93	Schlief et al.
	BD5	5,204,108	04/20/93	Illum
	BE5	5,204,113	04/20/93	Hartley et al.
	BF5	5,260,306	11/09/93	Boardman et al.
	BG5	5,271,961	12/21/93	Mathiowitz et al.
	вн5	5,306,483	04/26/94	Mautone
	BI5	5,327,883	07/12/94	Williams et al.
EXAMII	NER		DATE CONSIDERED	

PTO-144			ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716
OFF		ECOND SUPPLEMENTAL TION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a	al.
APR 1 1	ZUUS	April 2, 2003 Weral sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO. GROUP 1615
& TRADE	MARKON	7	.S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	BJ5	5,334,381	08/02/94	Unger
	вк5	5,340,587	08/23/94	Milhalko et al.
	BA6	5,352,435	10/04/94	Unger
	BB6	5,384,133	01/24/95	Boyes et al.
	BC6	5,393,524	02/28/95	Quay
	BD6	5,407,609	04/18/95	Tice et al.
	BE6	5,456,917	10/10/95	Wise et al.
	BF6	5,466,841	11/14/98	Horrobin et al.
	BG6	5,482,946	01/09/96	Clark et al.
	вн6	5,518,709	05/21/96	Sutton et al.
	B16	5,518,998	05/21/96	Bäckström et al.
	вј6	5,551,489	09/03/96	Trofast et al.
	вк6	5,580,575	12/03/96	Unger et al.
	BA7	5,607,695	03/04/97	Ek et al.
	BB7	5,607,915	03/04/97	Patton
	BC7	5,612,053	03/18/97	Baichwal et al.
	BD7	5,614,216	03/25/97	Janoff
	BE7	5,654,007	08/05/97	Johnson
	BF7	5,690,954	11/25/97	Illum
	BG7	5,698,721	12/16/97	Heath
	вн7	5,707,644	01/13/98	Illum
¥	BI7	5,709,884	01/20/98	Trofast et al.
	BJ7	5,780,014	07/14/98	Eljamal
	вк7	5,795,594	08/18/98	York et al.
	BA8	5,804,212	09/08/98	Illum
	BB8	5,814,607	09/29/98	Patton
EXAMI	NER		DATE CONSIDERED	

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	
O INFORMATION DISCLOSURE CITATION AN APPLICATION		AN APPLICATION	APPLICANT David A. Edwards, et al.		
APR (	<b>1 2003</b> Uśe sev	April 2, 2003	FILING DATE March 30, 2001	CONFIRMATION NO. GROUP 7248 1615	
PAT & TR	ADEMARY	,	U.S. PATENT DOCUMENTS		
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME	
	BC8	5,830,853	11/03/98	Bäckström, et al.	
	BD8	5,851,453	12/22/98	Hanna, et al.	
	BE8	This reference number intentionally left blank			
	BF8	5,874,063	02/23/99	Briggner <i>et al</i> .	
	BG8	This reference number intentionally left blank			
	вн8	5,885,613	03/23/99	Holland et al.	
	BI8	5,902,802	05/11/99	Heath	
	вј8	5,922,354	07/13/99	Johnson	
	вк8	5,928,469	07/27/99	Franks et al.	
	BA9	This reference number intentionally left blank			
	BB9	This reference number intentionally left blank			
	вс9	This reference number intentionally left blank			
	BD9	5,993,783	11/30/99	Eljamal	
	BE9	This reference number intentionally left blank			
	BF9	This reference number intentionally left blank			
	BG9	This reference number intentionally left blank			
	внэ	6,019,968	02/01/00	Platz	
	BI9	This reference number intentionally left blank			
	BJ9	6,051,256	04/18/00	Platz	
	вк9	6,063,138	05/16/00	Hanna et al.	
	BA10	This reference number intentionally left blank			
	BB10	6,080,721	06/27/00	Patton	
	BC10	This reference number intentionally left blank			
EXAMI	NER		DATE CONSIDERED		

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION AN APPLICATION			ATTORNEY DOCKET NO. 2685.1003-008 APPLICATION NO. 09/822,716	
		TION DISCLOSURE CITATION AN APPLICATION	APPLICANT David A. Edwards, et al.	
APR 1	<b>1 2003</b> Use se <b>d</b>	april 2, 2003  ral sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO. GROUP 7248 1615
VE TRA	DEMARK		U.S. PATENT DOCUMENTS	
EXAM- INER INI- IIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
<del>.</del>	BD10	6,103,270	08/15/00	Johnson
	BE10	6,123,936	09/26/00	Platz
	BF10	This reference number intentionally left blank		
	BG10	6,136,346	10/24/00	Eljamal
	вн10	6,153,224	11/28/02	Staniforth
	BI10	6,187,330 B1	02/13/01	Wang et al.
	BJ10	6,187,344 B1	02/13/01	Eljamal
	BK10	6,231,851 B1	05/15/01	Platz
	BA11	6,258,341 B1	07/10/01	Foster
	BB11	6,303,582 B1	10/16/01	Eljamal
	BC11	6,309,671 B1	10/30/01	Foster
	BD11	6,315,983 B1	11/13/01	Eistetter
	BE11	6,358,530 B1	03/19/02	Eljamal
	BF11	6,426,210 B1	07/30/02	Franks et al.
	BG11	6,433,040 B1	08/13/02	Dellamary et al.
	ВН11	This reference number intentionally left blank		
	BI11	US2002/0052310 A1	05/02/02	Edwards et al.
EXAMII	NER		DATE CONSIDERED	

ATTORNEY DOCKET NO. APPLICATION NO. PTO-1449 REPRODUCED 2685.1003-008 09/822,716 SECOND SUPPLEMENTAL ENERGMATION DISCLOSURE CITATION IN AN APPLICATION APPLICANT David A. Edwards, et al. APR 1 1 2003 & April 2, 2003 FILING DATE CONFIRMATION NO. GROUP March 30, 2001 7248 1615 everal sheets if necessary) (Use TRADEMA FOREIGN PATENT DOCUMENTS SUB-TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS CLASS YES BL WO 80/02365 13/11/80 PCT 04/12/86 PCT WO 86/06959 BNWO 88/04556 30/06/88 PCT 01/12/88 PCT WO 88/09163 BP 18/04/91 WO 91/04732 PCT BQ WO 91/06286 16/05/91 PCT BL2 16/05/91 PCT WO 91/06287 BM2 05/09/91 PCT WO 91/12823 This reference number intentionally left blank BO2 29/10/92 PCT WO 92/18164 BP2 WO 92/21382 10/12/92 PCT BQ2 23/12/93 WO 93/25221 PCT BL3 03/03/94 PCT WO 94/04133 вмз WO 94/07514 14/04/94 PCT BN3 WO 94/08627 28/04/94 PCT BO3 04/08/94 WO 94/16739 PCT BP3 05/01/95 PCT WO 95/00127 BQ3 WO 95/07072 16/03/95 PCT BL4 WO 95/24183 14/09/95 PCT PCT (Platz) BM4 23/11/95 WO 95/31479 BN4 WO 95/35097 28/12/95 PCT BO4 WO 96/09814 04/04/96 PCT BP4 This reference number intentionally left blank BQ4 WO 96/23485 08/08/96 PCT BL5 WO 96/32096 17/10/96 PCT (Eljamal) BM5 WO 96/32116 17/10/96 PCT (Eljamal) 17/10/96 PCT (Platz) WO 96/32149 DATE CONSIDERED EXAMINER

Sheet 7 of 16 APPLICATION NO. `PTO-1449 REPRODUCED ATTORNEY DOCKET NO. 2685.1003-008 09/822,716 SECOND SUPPLEMENTAL APPLICANT INFORMATION DISCLOSURE CITATION David A. Edwards, et al. IN AN APPLICATION April 2, 2003 CONFIRMATION GROUP FILING DATE NO. March 30, 2001 1615 veral sheets if necessary) 7248 FOREIGN PATENT DOCUMENTS SUB-TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS CLASS YES B<sub>0</sub>5 WO 96/40963 19/12/96 PCT 27/12/96 PCT WO 96/41873 **BO5** WO 97/03649 06/02/97 PCT BL6 WO 97/36574 09/10/97 PCT BM6 This reference number intentionally left blank BN6 23/04/98 WO 98/16205 PCT (Foster) B06 WO 98/29096 09/07/98 PCT (Gordon) 09/07/98 PCT (Gordon) WO 98/29098 BQ6 WO 98/29140 09/07/98 PCT (Gordon) BL7 WO 98/29141 09/07/98 PCT (Gordon) BM7 This reference number intentionally left blank BN7 19/11/98 PCT WO 98/51278 **BO7** WO 99/16419 08/04/99 PCT WO 99/16420 08/04/99 PCT BO7 WO 99/16421 08/04/99 PCT BL8 08/04/99 PCT WO 99/16422 BM8 29/12/99 PCT WO 99/66903 BN8 This reference number intentionally left blank BO8 23/03/00 PCT (Clark) WO 00/15262 BP8 (Clark) WO 00/21594 20/04/00 PCT BQ8 WO 00/33811 15/06/00 PCT BL9 04/01/01 PCT (Bennett) WO 01/00312 A1 BM9 01/03/01 PCT WO 01/13891 A3 BN9 10/05/01 PCT (Lechuga-WO 01/32144 A1 Ballesteros)

DATE CONSIDERED

EXAMINER

'PTO-144	9 REPROI	DUCED		ATTORNEY DOCKET NO.	APPLICAT	ION NO.	Sheet 8	ot 16
į		GEGOVE GUDDI EVENENI		2685.1003-008	09/822	,716		
101	PIE	SECOND SUPPLEMENTAL RMATION DISCLOSURE CI IN AN APPLICATION		APPLICANT David A. Edwards,	et al.			
APR	1 1 2005 (Use	April 2, 2003	ssary)	FILING DATE March 30, 2001	CONFIRMA 7248	TION NO.	GROUP 1615	
PATE .	BANEMA			PATENT DOCUMENTS	<u> </u>		<b></b> -	
	have	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSI YES	NOITA ON
	в09	WO 02/09669 A3	07/02/00	PCT (Snyder)				
	BP9	WO 02/11695 A3	14/02/02	PCT (Stevenson)				
	BQ9	WO 02/054868 A2	18/07/02	PCT (Weickert)				
	BL10	WO 02/055101 A2	18/07/02	PCT (Hastedt)				
	BM10	WO 02/087542 A1	07/11/02	PCT (Bot)				
	BN10	EP 0 072 046 A1	16/02/03	EPO				
	BO10	EP 0 213 303 B1	04/09/91	EPO				
**	BP10	EP 0 257 915 A1	02/03/88	EPO		-		
	BQ10	EP 0 257 956 B1	20/05/92	EPO				
	BL11	EP 0 324 938 A1	26/07/89	EPO				
	BM11	EP 0 335 133 A2	04/10/89	EPO				
	BN11	EP 0 458 745 A1	14/05/91	EPO	_			
	B011	EP 0 510 731 A1	28/10/92	EPO				
	BP11	EP 0 634 166 A1	18/01/95	EPO				
	BQ11	EP 0 656 206 A1	07/06/95	EPO				
	BL12	1 288 583	17/11/69	GB				
	BM12	1,300,009	05/05/92	Canada				
	BN12	1,302,258	02/06/92	Canada				
	BO12	2,058,428	05/09/00	Canada				
	BP12	2,085,884	30/12/91	Canada				
	BQ12	2,111,002	22/08/00	Canada				
	BL13	2,126,244	26/09/00	Canada				

EXAMINER

BM13

BN13

2,166,108

2,170,394

DATE CONSIDERED

Canada

Canada

05/01/95

02/03/95

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	
OIP		SECOND SUPPLEMENTAL MATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a	······································	
APR 1	(në <b>e</b>	April 2, 2003 Several sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO. 7248	GROUP 1615
ENT & TR	ADEMA	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	Pages, Etc.)	
	BR	This reference number intentional	lly left blank.		
	BS	Adjei, A., and Garren, J., "P Particle Size on Bioavailabil Volunteers," <i>Pharm. Res.</i> , 7(6	ity of Leuprolide Acetate	ide Drugs: Effe in Healthy Mal	ect of e
	вт	Allen, T.M., et al., "Subcuta with the Intravenous and Intr Biophys. Acta. 1150:9-16 (199	aperitoneal Routes of Inj	iposomes: A Com ection," Bioche	mparison em. et
	BU	Altshuler, B., et al., "Aeros Am. Med. Assoc. Arch. of Indu	ol Deposition in the Huma st. Health 15:293-303 (19	n Respiratory T	ract,"
	BV	Anderson, P.J., et al., "Effe Boluses," Am. Rev. Respir. Di	ct of Cystic Fibrosis on s., 140:1317-1324 (1989).	Inhaled Aerosol	
	BW	Anderson, M., et al., "Human Inhaled with an Extremely Low	Deposition and Clearance Flow Rate," Exp. Lung Re	of 6-µm Particl es., 21:187-195	es (1995).
	вх	Barrera, D.A., et al., "Synthesis and RGD Peptide Modification of a New Biodegradable Copolymer: Poly(lactic acid-co-lysine)," J. Am. Chem. Soc., 115:11010-11011 (1993).			Soc.,
	вұ	Beck, L.R., et al., "A New Lo Administration of Progesteron (1979).	ng-Acting Injectable Micr e," Fertility and Sterili	ocapsule System	for the
	BZ	Benita, S., et al., "Characte Microspheres," J. of Pharm. S	rization of Drug-loaded P ci 73(12):1721-1724 (1984	oly( <i>d,1</i> -lactide	e)
	BR2	Blackett, P.M., and G. Buckto Interaction of Surfactants wi Salbutamol Sulphate in a Mode Research, 12(11):1689-1693 (1	th Crystalline and Partia l Inhalation Aerosol Syst	lly Crystalline	<b>:</b>
	BS2	Brain, J.D., "Physiology and The Reticuloendothelial Syste York), pp. 315-327 (1985).	Pathophysiology of Pulmon m, Reichard and Filkins,	ary Macrophages eds. (Plenum Pr	s". In cess, New
	BT2	Brown, A.R., et al., "Propell Potential Therapeutic Agents 28:241-257 (1994).	ant-Driven Aerosols of Fu in the Respiratory Tract,	nctional Protei " Immunopharmac	ns as
	BU2	Byron, P.R., "Determinants of Aerosols Delivered to the Lun	Drug and Polypeptide Biog," Adv. Drug. Del. Rev.,	pavailability fr 5:107-132 (199	com 90).
	BV2	Carroll, B.A., et al., "Gelat Ultrasonic Contrast Agents,"	in Encapsulated Nitrogen Investigative Radiology,	Microbubbles as 15:260-266 (198	; 30).
	BW2	Carroll, B.A., et al., "Ultra Encapsulated Microbubbles," R	sonic Contrast Enhancemen adiology, 143:747-750 (19	t of Tissue by	
	BX2	Ch'ng, H.S., et al., "Bioadhe Drug Delivery II: Synthesis a Bioadhesive Polymers," J. of	nd Evaluation of Some Swe	elling, Water-In	rolled soluble
EXAMIN	NER	. —	DATE CONSIDERED		

PTO-1449	PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2685.1003-008	, , , , , , , , , , , , , , , , , , , ,	
OVE		SECOND SUPPLEMENTAL MATION DISCLOSURE CITATION WIN AN APPLICATION	APPLICANT David A. Edwards, et al.		
APR 1	1 2005	April 2, 2003	FILING DATE	CONFIRMATION NO.	GROUP
Par I	(Use	theral sheets if necessary)	March 30, 2001	7248	1615
187	RADEUN	OTHER DOCUMENTS (Including Aut	hor, Title, Date, Pertinent	Pages, Etc.)	
	BY2	Clark, A., and P. Byron, "Dep Aerosol Particle Size," Z. Er	endence of Pulmonary Abso krank. Atm.org., 166:13-2	orption Kinetics 4 (1986).	on
	BZ2	Clark, A.R., and M. Egan, "Mo Aerosols," J. Aerosol Sci., 2	deling the Deposition of 5(1):175-186 (1994).	Inhaled Powdere	ed Drug
	BR3	Clay, M.M., et al. "Effect of Nebulised Terbutaline in Asth	Aerosol Particle Size or matic Subjects," <i>Thorax</i> 4	Bronchodilatat 1:364-368(1986)	ion with
	BS3	Cohen, S., et al., "Controlle Poly(Lactic/Glycolic Acid) Mi	d Delivery Systems for Pr crospheres," <i>Pharm. Res</i> .	roteins Based on 8(6):713-720(19	991).
	втз	Colthorpe, P., et al., "The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheal and Aerosol Administration to the Rabbit,"  Pharm. Res. 9(6):764-768 (1992).			
	BU3	Daly, W.H., et al., "The Prep Using Bis(Trichloromethyl) Ca (1988).	aration of N-Carboxyanhyd rbonate," Tetrahedron Let	lrides of α-Amir ct., 29(46):5859	no Acids 9-5862
	BV3	Damms, B. and W. Bains, "The Controlled Release, 8-11 (199	Cost of Delivering Drugs 6).	without Needles	s," J.
	BW3	Darquenne, C., and M. Paiva, Transport and Deposition in A Physiology, 80(4):1401-1414 (	lveolar Zone of Human Lun	d Simulations on sign," Journal of	of Aerosol Applied
	вхз	Davies, C.N., et al., "Breath J. of Appl. Physiol. 32(5):59	ing of Half-micron Aerosc 1-600(1972).	ols. I. Experime	ental.,"
	вуз	Davis, S.S., and L. Illum, "P Biomaterials, 9:111-115 (1988		Drug Carriers,"	,
	BZ3	Davis, S.S., et al., "Microsp Parenteral and Nasal Administ 15, pp. 201-213 (1987).	heres as Controlled-Relearation," Controlled Relea	se Systems for ase Technology,	Chapter
	BR4	Dorries, A.M., and Valberg P. Versus Instilled Material," A	A., "Heterogeneity of Pha m. Rev. Respir. Dis., 146	gocytosis for I 5:831-837 (1992)	nhaled
	BS4	This reference number intentional	lly left blank.		
	BT4	This reference number intentional	lly left blank.		
	BU4	Eldridge, J. H., et al., "Bio System," Mol. Immunol., 28(3)		as a Vaccine Del	ivery
	BV4	Feinstein, S.B., et al., "Two Vitro Development and Quantit 3(1):14-20 (1984).	-Dimensional Contrast Ech ative Analysis of Echo Co	nocardiography lontrast Agents,"	I. In JACC
	BW4	Ferin, J., et al., "Pulmonary Rats," Am. J. Respir. Cell Mo	Retention of Ultrafine a 1. Biol. 6:535-542 (1992)	and Fine Particl	es in
EXAMIN	IER		DATE CONSIDERED		

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2685.1003-008 APPLICATION NO. 09/822,716	
	SECOND SUPPLEMENTAL		<u> </u>
II & ETNEO	RMATION DISCLOSURE CITATION IN AN APPLICATION	David A. Edwards, et a	al.
R 1 1 2003	April 2, 2003	FILING DATE	CONFIRMATION NO. GROUP
	several sheets if necessary)	March 30, 2001	7248 1615
PADEMARK	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinen	t Pages, Etc.)
BX4	Findeisen, W. "Uber Das Abset Der Menshlichen Lunge Bei Der 379 (1935).	zen Kleiner, in Der Luft Atmung," Pflugers Arch.	Suspendierter Teilchen in D. Ges. Physiol. 236:367-
BY4	This reference number intentiona	lly left blank.	
BZ4	Ganderton, D., "The Generatio Aggregates," J. Biopharmaceut	n of Respirable Clouds Foical Sciences, 3(1/2):101	orm Coarse Powder 1-105 (1992).
BR5	Gehr, P. et al., "Surfactant Structural, Stereological, an 26:423-436 (1993).		
BS5	Gerrity, T.R., et al., "Calcu Airway Generations of Normal	lated Deposition of Inhal Subjects," J. Appl. Phys.	ed Particles in the ., 47(4):867-873 (1979).
BT5	This reference number intentiona	lly left blank.	
BU5	Gonda, I., "Preface. Major Is Therapeutic and Diagnostic Ag Rev. 5:1-9 (1990).	sues and Future Prospects ents to the Respiratory T	s in the Delivery of Tract," Adv. Drug Del.
BV5	This reference number intentiona	lly left blank.	
BW5	Gonda, I., "Targeting by Depo Technology (ed. A.J. Hickey),	sition," in Pharmaceutica Marcel Dekkar Inc., pp.	al Inhalation Aersol 61-82, New York (1992).
BX5	Gurny, R., et al., "Bioadhesi Analysis," Biomaterials, 5:33	ve Intraoral Release Syst 6-340 (1984).	ems: Design, Testing and
BY5	This reference number intentiona	lly left blank.	
BZ5	This reference number intentiona	lly left blank.	
BR6	Heyder, J.; and G. Rudolf, "M human respiratory tract," J.		
BS6	Heyder, J., et al., "Total De Respiratory Tract for Nose an (1975).	position of Aerosol Parti d Mouth Breathing," J. As	cles in the Human erosol Sci., 6:311-328
вт6	Hickey, A.J., et al., "Use of Drugs from Dry Powder Aerosol (1992).	Particle Morphology to Is," J. Biopharmaceutical	Influence the Delivery of Sci., 3(火):107-113
BU6	Hirano, S., et al., "Pulmonar into the Rat Lung," Arch. of	y Clearance and Toxicity Toxicology, 63:336-342 (1	of Zinc Oxide Instilled
BV6	Hrkach, et al., "Synthesis of Copolymers," Macromolecules,	Poly(L-lactic acid-co-L- 28(13):4736-4739 (1995).	-lysine) Graft
EXAMINER		DATE CONSIDERED	

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2685.1003-008	APPLÍCATION NO. 09/822,716		
OIP	EMECK C	SECOND SUPPLEMENTAL  RMATION DISCLOSURE CITATION  IN AN APPLICATION	APPLICANT David A. Edwards, et a	al.		
APR 1 1	MISE,	April 2, 2003	FILING DATE March 30, 2001	CONFIRMATION NO. 7248	GROUP 1615	
WE TRA	DEMARK	OTHER DOCUMENTS (Including Aut	thor, Title, Date, Pertinent	Pages, Etc.)		
	BW6	Hrkach, J.S., et al., "Poly(L Class of Functional Biodegrade Polymers for Bioapplications, Ottenbrite, et al., Eds., Ame: 1996.	able Biomaterials" in Hyd ACS Symposium Series No.	rogels and Biod 627, Raphael M	legradable I.	
	BX6	Illum, L., et al., "Bioadhesi System," Int. J. of Pharm. 39		ntial Nasal Dru	g Delivery	
	BY6	Johnson, M.A., et al. "Delive Nebulizer Systems in Chronic & Chest, 96:6-10 (1989).	ry of Albuterol and Iprat Stable Asthma: Efficacy a	rophiumbromide nd Pulmonary De	from Two position,"	
	BZ6	Kao, Y.J., and R.L. Juliano, "Interactions of Liposomes with the Reticuloendothelial System, Effects of Reticuloendothelial Blockade on the Clearance of Large Unilamellar Vesicles," <i>Biochimica et Biophys</i> . Acta. 677:453-461 (1981).				
	BR7	Kassem, N.M., and D. Ganderton Characteristics of Inspirable 42(Supp):11 (1990).				
	BS7	This reference number intentional	lly left blank.			
	BT7	Kobayashi, S. et al., "Pulmonary Delivery of Salmon Calcitonin Dry Powders Containing Absorption Enhancers in Rats," Pharm. Res., 13(1):80-83 (1996).				
	BU7	Kohler, D., "Aerosols for Sys	temic Treatment" Lung, Su	ppl: pp. 677-68	4 (1990).	
	BV7	Komada, F. et al., Intratrache Absorption from Solution and 1 863-867 (June, 1994).	eal Delivery of Peptide a Dry Powder by Rat Lung,"	nd Protein Agen J. Pharm. Sci.,	ts: 83(6):	
	BW7	This reference number intentional	ily left blank.			
	BX7	Kricheldorf, H.R. "α-Aminoacio Springer-Verlag, Berlin (1987)		d Related Heter	ocycles,"	
	BY7	Kwok, K.K., et al., "Production Microcapsules by an Air Atomic (1991).	on of 5-15 μm Diameter Al zation Technique," Pharm.	ginate Polylysi Res., 8(3):341	ne -344	
	BZ7	Lai, Y-L., et al., "Sustained Poly(Glycolide-co-Lactide) Mid			(1993).	
	BR8	Lai, W.C., et al., "Protection Genetic Vaccination," DNA and	n Against <i>Mycoplasma Pulm</i> Cell Biology, 14(7):643-	ninosis Infectio 651 (1995).	n by	
	BS8	Landahl, "On The Removal of A I. The Lung," Bull. Math. Bio	ir-borne Droplets by The phys., 12:43-56 (1950).	Human Respirato	ry Tract:	
	BT8	Langer, R., "New Methods of D	rug Delivery", Science, 2	49:1527-1533 (1	990).	
:	BU8	Le Corre, P., et al., "Prepara Polylactide and Polylactide-Co Pharmaceutics, 107:41-49 (1994	o-Glycolide Microspheres,		e-Loaded	
EXAMIN	IER		DATE CONSIDERED			

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2685.1003-008 APPLICATION NO. 09/822,716		
INFOR	SECOND SUPPLEMENTAL MATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a	21.	
APR 1 1 2003	April 2, 2003 everal sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO. 7248	GROUP 1615
	OTHER DOCUMENTS (Including Au	the With Date Portings	Pages Fts.	l
TRADEWARKS				
BV8	Leone-Bay, A., et al., "Micro Amino Acids: Properties, Mol calcitonin," J. of Med. Chem	ecular Modeling, and Oral	Delivery of Sa	
BW8	Liu, F., et al., "Pulmonary : Res. 10(2):228-232 (1993).	Delivery of Free and Lipo	somal Insulin,"	Pharm.
BX8	Liu, W.R., et al., "Moisture the Solid State," Biotechnol			eins in
BY8	This reference number intention	ally left blank.		
BZ8	Martonen, T.B., "Mathematica Pharmaceuticals", J. of Pharm	l Model for the Selective m. <i>Sci.</i> , 82(12):1191-1198	Deposition of (1993).	Inhaled
BR9	Masinde, L.E., and Hickey, A Lactic Acid) Microspheres,"	.J., "Aerosolized Aqueous Int. J. of Pharmaceutics,	Suspensions of 100:123-131 (1	Poly(L- .993).
BS9	Mathiowitz, E., et al., "Nove Polymers, 6:275-283 (1987).	el Microcapsules for Deli	very Systems,"	Reactive
BT9	Mathiowitz, E., et al., "Polyanhydride Microspheres. IV. Morphology and Characterization of Systems Made by Spray Drying," J. of Appl. Polymer Sci. 45:125-134 (1992).			
BU9	Mathiowitz, E., et al., "Morphology of Polyanhydride Microsphere Delivery ASystems," Scanning Microscopy, 4(2):329-340 (1990).			
'BV9	Mathiowitz, E., and R. Lange Hot-Melt Microencapsulation,	r, "Polyanhydride Microsp " J. of Controlled Releas	heres as Drug ( e 5:13-22 (1987	arriers I.
BW9	Mathiowitz, E., et al., "Polyanhydride Microspheres as Drug Carriers. II. Microencapsulation by Solvent Removal," J. of Appl. Polymer Sci., 35:755-774 (1988).			3. II. 5:755-774
BX9	Ménache, M.G., et al., "Part Laboratory Animals," Annals	icle Inhalability Curves of Occupational Hygiene,	for Humans and 39(3):317-328 (	Small [1995].
вү9	This reference number intentions	ally left blank.		
BZ9	Morimoto, Y., and Adachi, Y. Phosphatidylcholine Upon Int Bull. 30(6):2248-2251 (1982)	ratracheal Administration	posomal to Rats," <i>Chem</i>	n. Pharm.
BR10	Mulligan, R.C., "The Basic So (1993).	cience of Gene Therapy",	Science, 260:92	6-932
BS10	This reference number intentions	ally left blank.		
BT10	This reference number intentions	ally left blank.		
BU10				
EXAMINER		DATE CONSIDERED		

	9 REPROD		ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	
OIP	ENFORM	SECOND SUPPLEMENTAL MATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a	al.	-
APR 1 1	2003 (Use	April 2, 2003 Several sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO. 7248	GROUP 1615
TRAD	MARKS	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	Pages, Etc.)	
N. C.	BV10	Newman, S.P., "Aerosol Depos Chest, 88(2):152S-160S (1985		nhalation Thera	ру,"
	BW10	Niven, R.W., et al., "The Pu Intratracheally Instilled rho 12(9):1343-1349 (1995).	lmonary Absorption of Aer G-CSF and monoPEGylated r	osolized and hG-CSF," Pharm.	Res.,
	BX10	Niven, R.W., et al., "Solute Lung. III. Absorption of Seve Poly (2-Hydroxyethyl)-Aspart	eral Peptidase-Resistant,	Synthetic Poly	peptides:
	BY10	Niwa, T., et al., "Aerosoliz Nanospheres for Pulmonary De 115(9):732-741 (1995).	ation of Lactide/Glycolid livery of Peptide-Drugs,"	e Copolymer (PL Yakugaku Zassh	GA) i,
	BZ10	Ogiwara, M., "Clearance and Maximum Removal Rate of Liposomes in Normal and Impaired Liver of Rat," Gastroenterologia Japonica, 19(1):34-40 (1984).			
	BR11	Okumura, K., et al., "Intratracheal Delivery of Insulin. Absorption from Solution and Aerosol by Rat Lung," Int. J. Pharmaceutics, 88:63-73 (1992).			
	BS11	This reference number intentionally left blank.			
	BT11	Patton, J.S., et al., "Bioavailability of pulmonary delivered peptides and proteins: $\alpha$ -interferon, calcitonins and parathyriod hormones," J. Controlled Release, 28:79-85 (1994).			
	BU11	Pavia, D., "Lung Mucociliary and Experimental Aspects, Cl London), pp. 127-155, (1984)	arke, S.W. and Pavia, D.,	and the Lung: eds.(Butterwor	Clinical ths,
	BV11	Peart, J. et al., "Multicompo Aerosols," J. Pharm. Res. 14			r
	BW11	Pinkerton, K.E., et al., "Ae. Lung Using Confocal Scanning 26:437-443 (1993).	rosolized Fluorescent Mic Laser Microscopy", <i>Micro</i>	rospheres Detec scopy Res. and	ted in the Tech.,
	BX11	Rudt, S., and R.H. Muller, " Microparticles by Chemilumin Particle Size and Particle Co	escence. I. Effect of Ana	lytical Paramet	ers,
	BY11	Rudt, S., et al., "In Vitro Phagocytosis Assay of Nano- and Microparticles by Chemiluminescence, IV. Effect of Surface Modification by Coating of Particles with Poloxamine and Antarox CO on the Phagocytic Uptake", J. of Contr. Rel. 25:123-132 (1993).			
	BZ11	Ruffin, R.E., et al., "The Pand Propranolol in Asthmatic	referential Deposition of Patients," Chest 80(6):9	Inhaled Isopro 04-907 (1981).	terenol
	BR12	Sela, M., et al., "Multichai: (1956).	n Polyamino Acids," J. Am	. Chem. Soc.,	78:746-751
	BS12	Smith, A.L., and B. Ramsey, Respiration, 62(suppl 1):19-	"Aerosol Administration o 24 (1995).	f Antibiotics,"	
EXAMIN	JER		DATE CONSIDERED		

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716				
10		SECOND SUPPLEMENTAL ATION DISCLOSURE CITATION ON APPLICATION	APPLICANT David A. Edwards, et a	21.				
APR	1 1 2003 (Use :	April 2, 2003	FILING DATE March 30, 2001	CONFIRMATION NO. 7248	GROUP 1615			
W. B.	(Use scral sheets if necessary)  March 30, 2001  7248  1615  TRADE OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BT12	Smith, P.L., "Peptide Delivery via the Pulmonary Route: A Valid Approach for Local and Systemic Delivery," J. of Contr. Rel., 46:99-106 (1997).						
	BU12		st, "Radiolabeled Colloids and Macromolecules in ical Reviews in Therapeutic Drug Carrier Systems,					
	BV12		ift, D., "The Oral Airway - A Conduit or Collector for Pharmaceutical rosols?" Respiratory Drug Delivery IV, 187-195 (1994).					
	BW12	Tabata, Y., et al., "Controlled Delivery Systems for Proteins Using Polyanhydride Microspheres," Pharm. Res. 10(4):487-496 (1993).						
	BX12	Tabata, Y., and Y. Ikada, "Effect of Surface Wettability of Microspheres on Phagocytosis," J. of Colloid and Interface Sci., 127(1):132-140 (1989).						
	BY12	Tabata, Y., and Y. Ikada, "Macrophage Phagocytosis of Biodegradable Microspheres Composed of L-lactic Acid/glycolic Acid Homo- and Copolymers," J. of Biomed. Mater. Res., 22:837-858 (1988).						
	BZ12	Tabata, Y., and Ikada, Y., "Effect of Size and Surface Charge of Polymer Microspheres on Their Phagocytosis by Macrophage," J. Biomed. Mater. Res., 22:837-843 (1988).						
	BR13	Taburet, A.M., and Schmit, B., "Pharmacokinetic Optimisation of Asthma Treatment," Clin. Pharmacokinet. 26(5):396-418 (1994).						
	BS13	Tansey, I.P., "The Challenges in the Development of Metered Dose Inhalation Aerosols Using Ozone-Friendly Propellants," Spray Technol. & Market, 4:26-29 (1994).						
	BT13	Timsina, M.P., et al., "Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers," Int. J. of Pharm., 101:1-13 (1994).						
	BU13	Turner, J.R., and S.V. Hering, "Greased and Oiled Substrates as Bounce-Free Impaction Surfaces," J. Aerosol Sci., 18(2):215-224 (1987).						
	BV13	This reference number intentionally left blank.						
	BW13	Wall, D.A., "Pulmonary Absorption of Peptides and Proteins," Drug Delivery, 2:1-20 (1995).						
	BX13	Warheit, D.B., and Hartsky, M.A., "Role of Alveolar Macrophage Chemotaxis and Phagocytosis in Pulmonary Clearance to Inhaled Particles: Comparisons Among Rodent Species," Microscopy Res. and Tech., 26:412-422 (1993).						
	BY13	Weiner, Norman et al., "Liposomes as a Drug Delivery System," Drug Development and Industrial Pharmacy, $15(10):1523-1554$ (1989).						
	BZ13	Wheatley, M.A., et al., "Contrast Agents for Diagnostic Ultrasound: Development and Evaluation of Polymer-Coated Microbubbles," Biomaterials 11:713-717 (1990).						
	BR14	Wichert, B., and Rohdewald, P., "Low Molecular Weight PLA: A Suitable Polymer for Pulmonary Administered Microparticles?," J. Microencapsulation, 10(2):195-207 (1993).						
EXAMIN	IER		DATE CONSIDERED					

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. '2685.1003-008	APPLICATION NO. 09/822,716				
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a	al.				
April 2, 2003  1 1 2003  (Use several sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO. 7248	GROUP 1615			
OTHER DOCUMENTS (Including A	thor, Title, Date, Pertinent	Pages, Etc.)				
Microbubbles," Mat. Res. Soc. Symp. Proc., 372:89-95 (1995).						
	Zanen, P., et al., "The Optimal Particle Size for $\beta$ -adrenergic Aerosols in Mild Asthmatics", Int. J. of Pharm., 107:211-217 (1994).					
BU14 Zanen, P., et al., "The Opti in Mild Asthmatics", Int. J.	Zanen, P., et al., "The Optimal Particle Size for Parasympathicolytic Aerosols in Mild Asthmatics", Int. J. of Pharm., 114:111-115 (1995).					
BV14 Zeng, X.M., et al., "The Cor Pharm., 124:149-164 (1995).	being, mining do dairy and demonstrate potentially of and and and and and					
	Albumin Microsphere Preparation by Central Composite Design," Int. J. of					
	-					
	<del> </del>					
EXAMINER	DATE CONSIDERED					